ArticleJournal of diabetes and metabolic disorders2026
The burden of diabetic retinopathy-related blindness and visual impairment in the global labor force from 1990 to 2021 and projections to 2050: Analysis based on the 2021 global burden of disease study.
Article in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Zinc finger DHHC-type containing 19 promotes retinal pigment epithelium cell proliferation via VEGFA palmitoylation in diabetic macular edema (DME).Journal of diabetes and metabolic disorders · 2026Article
- Anatomical-Functional Dissociation in Diabetic Macular Edema: Five-Year Outcomes of Treat-and-Extend Versus Pro Re Nata Anti-VEGF Regimens.Journal of clinical medicine · 2026Article
- MicroRNAs: A Social Network in Diabetic Retinopathy.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic retinopathy (DR) is a major microvascular complication of diabetes and is the leading cause of blindness and visual impairment among working-age populations worldwide. The loss of vision caused by diabetes significantly reduces the quality of life and has a major impact on the overall burden of visual impairment. This study assessed the global burden of blindness and visual impairment caused by diabetes among the working population from 1990 to 2021, and predicted the future trends in 2050. Methods: Based on data from the Global Burden of Disease Study 2021, we analyzed trends from 1990 to 2021 in the burden of diabetes-related blindness and visual impairment. Key metrics included case numbers and rates of prevalence and years lived with disability (YLDs). Decomposition analysis identified drivers of burden changes, and health inequality analysis assessed disparities by socioeconomic status. We used ARIMA and exponential smoothing models to forecast prevalence and YLDs from 2022 to 2050. Results: From 1990 to 2021, the global burden of blindness and visual impairment caused by diabetes among the working population significantly increased.From 1990 to 2021, the global burden of blindness and visual impairment caused by diabetes among the working population significantly increased. Comparative analysis shows that the number of cases of type 2 diabetes and the number of YLDs are much higher than those of type 1 diabetes. Moreover, the burden on women has always been higher than that on men. Conclusions: Among the working population, blindness and visual impairments caused by diabetes pose a serious and increasingly severe public health threat worldwide, with the impact on women being particularly significant.Among the working population, blindness and visual impairments caused by diabetes pose a serious and increasingly severe public health threat worldwide, with the impact on women being particularly significant. Therefore, urgent action is needed to raise awareness of diabetic retinopathy among both clinicians and the general public, improve the level of early detection and treatment, reduce preventable vision loss, and alleviate the impact on family life and social economic burden caused by this decline in quality of life. Therefore, urgent action is needed to raise awareness of diabetic retinopathy among both clinicians and the general public, improve the level of early detection and treatment, reduce preventable vision loss, and alleviate the impact on family life and social economic burden resulting from this decline in quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.